Loading
NDI-219216 is an experimental small-molecule drug from Nimbus Wadjet in phase 2 trials, aimed at WRN helicase (MSI-high cancers).
NDI-219216 is a small-molecule drug developed by Nimbus Wadjet. Its target is WRN helicase (MSI-high cancers) (the sponsor names WRN helicase). The sponsor states: NDI-219216 is a highly selective, non-covalent small-molecule inhibitor of WRN helicase activity that triggers a DNA damage response and suppresses viability selectively in microsatellite instability-high (MSI-H) tumour cells, a synthetic-lethal approach. ClinicalTrials.gov describes the intervention as: NDI-219216 is a highly selective small molecule inhibitor of WRN helicase activity. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06898450, plans to enrol 134 participants with primary completion expected 2031-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
NDI-219216 is a highly selective, non-covalent small-molecule inhibitor of WRN helicase activity that triggers a DNA damage response and suppresses viability selectively in microsatellite instability-high (MSI-H) tumour cells, a synthetic-lethal approach. Connects to WRN helicase (MSI-high cancers).
1.NDI-219216 slips into a pocket on WRN helicase (MSI-high cancers).
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"NDI-219216" OR ABSTRACT:"NDI-219216") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NDI-219216, not a curated reading list.
Shares WRN helicase (MSI-high cancers) and the tag pipeline.